Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Accounts Payables (2017 - 2025)

Eton Pharmaceuticals' Accounts Payables history spans 8 years, with the latest figure at $11.0 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 163.4% to $11.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.0 million, a 163.4% increase, with the full-year FY2025 number at $11.0 million, up 163.4% from a year prior.
  • Accounts Payables hit $11.0 million in Q4 2025 for Eton Pharmaceuticals, down from $14.3 million in the prior quarter.
  • Over the last five years, Accounts Payables for ETON hit a ceiling of $14.3 million in Q3 2025 and a floor of $1.1 million in Q3 2022.
  • Historically, Accounts Payables has averaged $3.8 million across 5 years, with a median of $2.1 million in 2022.
  • Biggest five-year swings in Accounts Payables: crashed 67.8% in 2022 and later soared 469.25% in 2025.
  • Tracing ETON's Accounts Payables over 5 years: stood at $1.8 million in 2021, then decreased by 0.45% to $1.8 million in 2022, then increased by 4.64% to $1.8 million in 2023, then skyrocketed by 125.49% to $4.2 million in 2024, then skyrocketed by 163.4% to $11.0 million in 2025.
  • Business Quant data shows Accounts Payables for ETON at $11.0 million in Q4 2025, $14.3 million in Q3 2025, and $12.1 million in Q2 2025.